Who we are

1. The company

Oriskami SAS is a French simplified joint-stock company (SAS), founded in 2021 in Saint-Grégoire (Brittany), and registered with the Tribunal de commerce de Rennes under SIREN 892 745 969 (VAT FR19892745969, NAF 7219Z). The registered office is at Parc EDONIA – Bâtiment M, rue des Îles Kerguelen, 35760 Saint-Grégoire, France. SAMRoute is the company's product line — software for the quantitative analysis of risks on transport infrastructure, with a current line of work on level-crossing characterisation across the French national network.

2. The founder

Fabrice Colas founded the company and runs the work. The fifteen years before SAMRoute were split between academic research in statistical learning and applied epidemiology, and production engineering of risk systems at scale.

2.1 Track record

PhD in statistical learning from Leiden University (2006–2009). Postdoctoral research positions at UCLA (Los Angeles), UMC Utrecht, and Leiden University Medical Center on the human genetics of autism, schizophrenia, and rheumatoid arthritis (2010–2013). A subsequent posting at the cardio-thoracic surgery department of CHU Rennes (2018–2019) added applied epidemio-statistical work in the clinical setting.

Full-stack engineering training at Hack Reactor (San Francisco, 2014). Between the academic and the SAMRoute years, applied risk-modelling work in production at Travix International (Amsterdam) recovered roughly €2.3M against live traffic — the same statistical methods, applied to a commercial portfolio rather than a clinical cohort.

2.2 Selected publications

Five recent peer-reviewed papers, in decreasing date order:

• Current results of left ventricular assist device therapy in France: the ASSIST-ICD registry. A Anselmi, V Galand, A Vincentelli, S Boule, C Dambrin, F Colas, et al. European Journal of Cardio-Thoracic Surgery 58(1):112–120 (2020). DOI: 10.1093/ejcts/ezaa055 — IF ~3.0
• The role of rare compound heterozygous events in autism spectrum disorder. BD Lin, F Colas, IJ Nijman, et al. Translational Psychiatry 10:204 (2020). DOI: 10.1038/s41398-020-00866-7 — IF ~6.2
• Long-term follow-up of the Shelhigh™ SuperStentless bioprosthesis aortic valve and valved conduit in a monocentric experience. F Le Bars, J Tomasi, R Belhaj Soulami, F Colas, A Anselmi, JP Verhoye. Journal of Cardiovascular Surgery (Torino) 61(6):776–783 (2020). DOI: 10.23736/S0021-9509.20.11219-9 — IF ~1.4
• Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. KR van Eijk, S de Jong, MPM Boks, T Langeveld, F Colas, JH Veldink, et al. BMC Genomics 13:636 (2012). DOI: 10.1186/1471-2164-13-636 — IF ~3.7
• Clinical subtypes of Parkinson's disease. SM van Rooden, F Colas, P Martínez-Martín, M Visser, D Verbaan, et al. Movement Disorders 26(1):51–58 (2011). DOI: 10.1002/mds.23346 — IF ~7.4

The fuller record is on the founder's LinkedIn profile.

2.3 Recognised R&D status

Beyond the company's own R&D credit, the founder holds a personal CIR-approved consultant agrément from the French Ministry of Research (Crédit d'Impôt Recherche), first granted in 2022 and renewed in May 2025 for the 2025–2027 cycle, with a parallel CII (Crédit d'Impôt Innovation) agrément. The two CIR positions sit alongside the company's own filings and are described in detail on the Research timeline; the consultant agrément is independently verifiable through the Ministry's published registry.

3. Where we work

The company operates from the greater Rennes metropolitan area. The registered office and development premises are in Saint-Grégoire (Ille-et-Vilaine, Brittany). Production workloads run on OVHcloud infrastructure in France; the residency, sub-processor, and access-control commitments that follow from this setup are listed in Trust & Security.

4. Reach us

For commercial enquiries, contact@samroute.com or +33 2 30 96 66 74. For privacy, GDPR, or DPA matters, legal@oriskami.com. For security or incident reports, security@samroute.com. For investor enquiries, investors@oriskami.com.